சாம் குல்கர்னி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சாம் குல்கர்னி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சாம் குல்கர்னி Today - Breaking & Trending Today

Fate offers glimpse at 'natural killer' cell therapy for leukemia


Published May 14, 2021
National Institutes of Allergy and Infectious Diseases. (2016). Human natural killer cell [Micrograph]. Retrieved from Flickr.
Dive Brief:
Fate Therapeutics on Thursday reported new results from two early-stage studies testing two types of experimental leukemia treatments that use natural killer cells, an emerging form of cancer immunotherapy.
Four of nine patients who received one Fate NK cell therapy showed evidence of a response, as did one of three who got a different type of NK cell therapy. There were no instances of the neurological or immune-related side effects seen with other forms of cell therapy and there were also no side effects that would prevent testing of higher doses, according to the company. ....

Benjamin Burnett , Daina Graybosch , Sam Kulkarni , Md Anderson Cancer Center , Dive Brief , Nkarta Therapeutics , Clinical Trials , Gene Therapy , பெஞ்சமின் பர்னெட் , சாம் குல்கர்னி , ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் , டைவ் சுருக்கமான , மருத்துவ சோதனைகள் , கீந் சிகிச்சை ,

Vertex bets another $900M on CRISPR treatment for blood diseases


Dive Brief:
For the last several years, Vertex and CRISPR Therapeutics have been co-developing a potential cure for two blood disorders. On Tuesday, the companies said they amended their agreement so that Vertex takes on more of the associated costs, but also more of the profits should the therapy come to market.
The new agreement directs 60% of development costs and profits from future sales to Vertex, reflecting a 10% increase in both figures. CRISPR is now responsible for 40% of costs and would receive 40% of the profits. The revised terms also hand CRISPR a $900 million upfront payment, with the potential for $200 million more upon the first approval of the therapy, known as CTX001. ....

Sam Kulkarni , Brian Skorney , Dive Brief , Biopharma Dive , Nobel Prize , சாம் குல்கர்னி , டைவ் சுருக்கமான , நோபல் ப்ரைஸ் ,

From crude surgery to gene editing: how cancer treatments evolved over the years


A little more than
two centuries ago, an English novelist named Frances Burney endured a “terrible operation” to remove a tumour after having breast cancer diagnosed.
Burney spent more than 17 agonising minutes under the scalpel as her surgeon in Paris cut away at her breast – all without anaesthetic.
She was 58 when the mastectomy was performed and lived another three decades, a happy outcome that went against the terrible odds faced by cancer patients at the time.
Fast forward to today and the cancer treatments being contemplated by Prof Dan Peer at Tel Aviv University in Israel are as sophisticated and precisely targeted as the one Burney suffered was crude. ....

France General , Frances Burney , Sam Kulkarni , Professor Dan Peer Of Tel Aviv University , Laboratory Of Precision Nanomedicine , Prof Dan Peer At Tel Aviv University , Prof Dan Peer , Tel Aviv University , Precision Nanomedicine , Dan Peer , Tel Aviv , Professor Dan Peer , Prof Peer , Cart Cell , Functional Genomics , Cart Cells , Crispr Therapeutics , Daniel Bardsley , பிரான்ஸ் ஜநரல் , பிரான்சிஸ் பர்னி , சாம் குல்கர்னி , ப்ரொஃபெஸர் டான் பியர் ஆஃப் தொலைபேசி அவிவ் பல்கலைக்கழகம் , ப்ரொஃப் டான் பியர் இல் தொலைபேசி அவிவ் பல்கலைக்கழகம் , ப்ரொஃப் டான் பியர் , தொலைபேசி அவிவ் பல்கலைக்கழகம் , டான் பியர் ,